11.40
price up icon7.55%   0.80
after-market Handel nachbörslich: 11.35 -0.05 -0.44%
loading
Schlusskurs vom Vortag:
$10.60
Offen:
$10.55
24-Stunden-Volumen:
750.44K
Relative Volume:
0.76
Marktkapitalisierung:
$458.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+6.24%
1M Leistung:
+14.80%
6M Leistung:
-46.60%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$10.48
$11.41
1-Wochen-Bereich:
Value
$10.26
$11.41
52-Wochen-Spanne:
Value
$4.17
$28.99

Septerna Inc Stock (SEPN) Company Profile

Name
Firmenname
Septerna Inc
Name
Telefon
650-338-3533
Name
Adresse
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Name
Mitarbeiter
75
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
SEPN's Discussions on Twitter

Vergleichen Sie SEPN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SEPN
Septerna Inc
11.40 458.06M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Septerna Inc Stock (SEPN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-18 Herabstufung Wells Fargo Overweight → Equal Weight
2024-11-19 Eingeleitet Cantor Fitzgerald Overweight
2024-11-19 Eingeleitet JP Morgan Overweight
2024-11-19 Eingeleitet TD Cowen Buy
2024-11-19 Eingeleitet Wells Fargo Overweight

Septerna Inc Aktie (SEPN) Neueste Nachrichten

pulisher
Jun 18, 2025

Septerna, Inc. Holds Virtual Annual Stockholders Meeting - TipRanks

Jun 18, 2025
pulisher
Jun 16, 2025

Driehaus Capital Management LLC Increases Stake in Septerna Inc - GuruFocus

Jun 16, 2025
pulisher
Jun 10, 2025

Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies - MSN

Jun 10, 2025
pulisher
Jun 06, 2025

Nuveen Asset Management LLC Buys New Stake in Septerna, Inc. (NASDAQ:SEPN) - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

Bank of America Corp DE Makes New Investment in Septerna, Inc. (NASDAQ:SEPN) - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Kalkine: Septerna Inc Gains Traction on NASDAQ 100 Index from Kalkine - Kalkine Media

Jun 04, 2025
pulisher
Jun 02, 2025

Septerna To Present At Jefferies Conference; SEP-631 Phase 1 Trial On Track For Q3 - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

Deutsche Bank AG Invests $239,000 in Septerna, Inc. (NASDAQ:SEPN) - Defense World

Jun 02, 2025
pulisher
May 29, 2025

Septerna to Present at Jefferies Global Healthcare Conference - The Manila Times

May 29, 2025
pulisher
May 29, 2025

GPCR Pioneer Septerna Reveals Latest Drug Discovery Progress at Major Jefferies Healthcare Event - Stock Titan

May 29, 2025
pulisher
May 28, 2025

Jane Street Group LLC Invests $600,000 in Septerna, Inc. (NASDAQ:SEPN) - Defense World

May 28, 2025
pulisher
May 23, 2025

Analysts Think These Stocks Could More Than Double in Value - Investing.com

May 23, 2025
pulisher
May 23, 2025

Analysts Think These Stocks Could More Than Double in Value - MarketBeat

May 23, 2025
pulisher
May 22, 2025

Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect? - MSN

May 22, 2025
pulisher
May 20, 2025

Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna - MSN

May 20, 2025
pulisher
May 20, 2025

Novo Nordisk Inks $2.2B Deal With Septerna: Retail’s Thrilled - MSN

May 20, 2025
pulisher
May 18, 2025

Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer - The Globe and Mail

May 18, 2025
pulisher
May 18, 2025

Novo Nordisk, Septerna Agree $2.2 Billion Obesity Pill Deal - MSN

May 18, 2025
pulisher
May 18, 2025

Cantor Fitzgerald Remains a Buy on Septerna, Inc. (SEPN) - The Globe and Mail

May 18, 2025
pulisher
May 18, 2025

Wells Fargo & Company Boosts Septerna (NASDAQ:SEPN) Price Target to $18.00 - Defense World

May 18, 2025
pulisher
May 17, 2025

Septerna First Quarter 2025 Earnings: US$0.49 loss per share (vs US$6.35 loss in 1Q 2024) - simplywall.st

May 17, 2025
pulisher
May 17, 2025

22,095 Shares in Septerna, Inc. (NASDAQ:SEPN) Bought by The Manufacturers Life Insurance Company - Defense World

May 17, 2025
pulisher
May 17, 2025

ETFs to Capitalize on the Novo Nordisk-Septerna Deal - MSN

May 17, 2025
pulisher
May 16, 2025

Novo Nordisk in pact with Septerna for oral obesity drugs - MSN

May 16, 2025
pulisher
May 16, 2025

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments - MSN

May 16, 2025
pulisher
May 16, 2025

Septerna: Novo's Investment In Incretin Program IntriguesOne For The Watchlist - Seeking Alpha

May 16, 2025
pulisher
May 16, 2025

Where Septerna Stands With Analysts - Benzinga

May 16, 2025
pulisher
May 16, 2025

Septerna: Deal With Novo Nordisk Is A Game Changer, While It Still Trades Well Below Net Cash - Seeking Alpha

May 16, 2025
pulisher
May 16, 2025

Cantor Fitzgerald lifts Septerna stock to $25 target, maintains overweight By Investing.com - Investing.com Nigeria

May 16, 2025
pulisher
May 16, 2025

Cantor Fitzgerald lifts Septerna stock to $25 target, maintains overweight - Investing.com

May 16, 2025
pulisher
May 16, 2025

Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership - PMLiVE

May 16, 2025
pulisher
May 16, 2025

Septerna price target raised to $18 from $11 at Wells Fargo - TipRanks

May 16, 2025
pulisher
May 16, 2025

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills - MSN

May 16, 2025
pulisher
May 16, 2025

Biotech Stocks Worth Watching – May 14th - Defense World

May 16, 2025
pulisher
May 16, 2025

Novo Nordisk (NVO) Deal Highlights Strategic Potential Amid Septerna Developments | NVO Stock News - GuruFocus

May 16, 2025
pulisher
May 15, 2025

Septerna, Inc.: Strategic Partnerships and Promising Pipeline Drive Buy Rating - TipRanks

May 15, 2025
pulisher
May 15, 2025

Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna - MSN

May 15, 2025
pulisher
May 15, 2025

Septerna reports Q1 EPS (49c), consensus (45c) - TipRanks

May 15, 2025
pulisher
May 15, 2025

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results - The Manila Times

May 15, 2025
pulisher
May 15, 2025

Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs - Contract Pharma

May 15, 2025
pulisher
May 15, 2025

Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk - MSN

May 15, 2025
pulisher
May 15, 2025

Novo Nordisk Inks $2.2 Billion Deal with Septerna to Advance Obesity and Diabetes Treatments - MSN

May 15, 2025
pulisher
May 15, 2025

Novo Nordisk, Septerna collaborate on developing GPCR therapies - World Pharmaceutical Frontiers

May 15, 2025
pulisher
May 14, 2025

Novo Nordisk Partners with Septerna for New Obesity Drug Development - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Novo Nordisk, Septerna Ink Up To $2.2B Obesity Drug Deal - Law360

May 14, 2025
pulisher
May 14, 2025

Novo Nordisk Looks To Septerna For Oral Obesity Options - insights.citeline.com

May 14, 2025
pulisher
May 14, 2025

Septerna joins a $2.2B obesity deal with Novo - BioWorld MedTech

May 14, 2025
pulisher
May 14, 2025

Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing - Investor's Business Daily

May 14, 2025

Finanzdaten der Septerna Inc-Aktie (SEPN)

Es liegen keine Finanzdaten für Septerna Inc (SEPN) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Septerna Inc-Aktie (SEPN) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Finer Jeffrey
CEO and President
Apr 03 '25
Option Exercise
2.76
5,000
13,800
826,907
Ezekowitz Alan
Director
Mar 07 '25
Buy
6.93
13,319
92,270
117,420
Ezekowitz Alan
Director
Mar 06 '25
Buy
6.00
41,355
248,130
104,101
Ezekowitz Alan
Director
Mar 05 '25
Buy
5.82
37,835
220,260
62,746
Ezekowitz Alan
Director
Mar 04 '25
Buy
6.35
7,491
47,544
24,911
Finer Jeffrey
CEO and President
Feb 25 '25
Buy
5.68
10,000
56,765
764,907
Finer Jeffrey
CEO and President
Feb 26 '25
Buy
5.70
4,000
22,796
768,907
Finer Jeffrey
CEO and President
Feb 27 '25
Buy
5.80
3,000
17,400
771,907
Labrucherie Gil M
Chief Financial Officer
Feb 25 '25
Buy
5.59
6,282
35,116
36,282
Labrucherie Gil M
Chief Financial Officer
Feb 27 '25
Buy
5.85
3,718
21,750
40,000
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):